Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > While we're at it ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Comment by davgroon May 26, 2022 10:57am
160 Views
Post# 34709044

RE:While we're at it ...

RE:While we're at it ...
MrMugsy wrote: Any bets on when his troll friends show up?
Usually right behind him ... just a couple steps behind.

Same guy or similar ?


Stutters fits the mold of your typical Stockhouse Internet troll.  He showed up on Stockhouse exactly 6 months ago and has only posted in the ATE board.  He shares nothing of value on this board and tries to start a "Flame War" with every post. 

I have learned to ignore trolls like him, unless of course you find his antics entertaining (like I do with the Dumpster340).  The other sure fire way of silencing a troll is to provide facts and evidence that proves them wrong.  I suspect stutters is a disgruntled ex-ATE shareholder who lost large and is now lashing out with the sole intent of provoking emotional responses from others.  Trolls feed on this type of response.

In hindsight, I could have made a fortune if I had invested in the manufacturer of "Troll B Gone".  Demand for their product is skyrocketing as the unabated rise in Internet trolls continues.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities